New treatment for multiple sclerosis.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab